Literature DB >> 26096944

Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.

Mohammed Al-Hamadani1, Thomas M Habermann2, James R Cerhan3, William R Macon4, Matthew J Maurer3, Ronald S Go2,5.   

Abstract

The World Health Organization classification of non-Hodgkin lymphoma (NHL) was introduced in 2001. However, its incorporation into clinical practice is not well-described. We studied the distribution of NHL subtypes in adults diagnosed from 1998 to 2011, evaluated time trends, geo-demographic correlates, and changes in 5-year overall survival (OS). We obtained data prospectively collected by the National Cancer Data Base, which covers 70% of US cancer cases. There were 596,476 patients diagnosed with NHL. The major subtypes were diffuse large B-cell (32.5%), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; 18.6%), follicular (17.1%), marginal zone (8.3%), mantle cell (4.1%), peripheral T-cell not-otherwise-specified (1.7%), Burkitt (1.6%), hairy cell (1.1%), lymphoplasmacytic (1.1%), and NHL not-otherwise-specified (10.8%). Over the study period, the proportion of NHL not-otherwise-specified declined by half, while marginal zone lymphoma doubled. The distribution of major and rare NHL subtypes varied according to demographics but less so geographically or by type of treatment facility. We noted several novel findings among Hispanics (lower proportion of CLL/SLL, but higher Burkitt lymphoma and nasal NK/T-cell lymphoma), Asians (higher enteropathy-associated T-cell and angioimmunoblastic T-cell lymphomas), Blacks (higher hepatosplenic T-cell lymphoma), and Native Americans (similar proportions of CLL/SLL and nasal NK/T-cell lymphoma as Asians). With the exception of peripheral T-cell not-otherwise-specified and hairy cell leukemia, 5-year OS has improved for all the major NHL subtypes.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26096944     DOI: 10.1002/ajh.24086

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  78 in total

1.  Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project.

Authors:  Anamarija M Perry; Jacques Diebold; Bharat N Nathwani; Kenneth A MacLennan; Hans K Müller-Hermelink; Martin Bast; Eugene Boilesen; James O Armitage; Dennis D Weisenburger
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

2.  Composite Diffuse Large B-cell and Mantle Cell Lymphoma: A Case Report.

Authors:  Farhan Mohammad; Gwenalyn Garcia; Shiksha Kedia; Juan Ding; Matthew Hurford; Alexander Bershadskiy
Journal:  Cureus       Date:  2017-01-08

3.  Resistance mechanism for ibrutinib in marginal zone lymphoma.

Authors:  Narendranath Epperla; Arwa Y Shana'ah; Dan Jones; Beth A Christian; Sabarish Ayyappan; Kami Maddocks; Jennifer A Woyach
Journal:  Blood Adv       Date:  2019-02-26

Review 4.  Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.

Authors:  Bradley M Haverkos; Zenggang Pan; Alejandro A Gru; Aharon G Freud; Rachel Rabinovitch; Meng Xu-Welliver; Brad Otto; Carlos Barrionuevo; Robert A Baiocchi; Rosemary Rochford; Pierluigi Porcu
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 5.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

Review 6.  Update on the Treatment of Anaplastic Large Cell Lymphoma.

Authors:  Khoan Vu; Weiyun Ai
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

7.  Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.

Authors:  Umar Farooq; Matthew J Maurer; Carrie A Thompson; Gita Thanarajasingam; David J Inwards; Ivana Micallef; William Macon; Sergei Syrbu; Tasha Lin; Yi Lin; Stephen M Ansell; Grzegorz S Nowakowski; Thomas M Habermann; James R Cerhan; Brian K Link
Journal:  Br J Haematol       Date:  2017-06-27       Impact factor: 6.998

8.  Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016.

Authors:  Manette A W Dinnessen; Marjolein W M van der Poel; Sanne H Tonino; Otto Visser; Nicole M A Blijlevens; Daphne de Jong; King H Lam; Marie José Kersten; Pieternella J Lugtenburg; Avinash G Dinmohamed
Journal:  Leukemia       Date:  2020-10-12       Impact factor: 11.528

9.  Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.

Authors:  Laura L Hester; Steven I Park; William A Wood; Til Stürmer; M Alan Brookhart; Jennifer L Lund
Journal:  Cancer       Date:  2018-12-11       Impact factor: 6.860

10.  Quality of life amongst lymphoma survivors in a developing country.

Authors:  Diana L C Ng; Y C Leong; Gin Gin Gan
Journal:  Support Care Cancer       Date:  2016-07-26       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.